nach oben

Erschienen in:

19.08.2016 | Article

Soluble CD163, adiponectin, C-reactive protein and progression of dysglycaemia in individuals at high risk of type 2 diabetes mellitus: the ADDITION-PRO cohort

verfasst von: Pia Deichgræber, Daniel R. Witte, Holger J. Møller, Mette V. Skriver, Bjørn Richelsen, Marit E. Jørgensen, Nanna B. Johansen, Annelli Sandbæk

Erschienen in: Diabetologia | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Aim/hypothesis

Our aim was to investigate the association between the macrophage-activation marker soluble CD163 (sCD163), adiponectin, C-reactive protein (CRP) and changes in glycaemia, insulin resistance and insulin secretion in individuals at high risk of type 2 diabetes mellitus.

Methods

This prospective study included 1014 individuals at high risk of type 2 diabetes mellitus participating in the Danish arm of the Anglo-Danish-Dutch study of Intensive Treatment In PeOple with ScreeN-detected Diabetes in Primary Care (ADDITION-Europe trial) baseline examination in 2001–2006 and follow-up examination (ADDITION-Progression [ADDITION-PRO]) in 2009–2011. Baseline serum samples were analysed for sCD163, adiponectin and CRP. The associations between sCD163, adiponectin and CRP per doubling of concentration, and changes per year in HbA_1c, fasting plasma glucose, 2 h glucose, fasting insulin, HOMA-IR and HOMA-β were assessed using a mixed-effects model.

Results

A doubling of sCD163 concentration was positively associated with changes in HOMA-β (β = 1.160 per year, 95% CI 0.345, 1.975) as well as a doubling of CRP concentration (β = 0.410 per year, 95% CI 0.051, 0.769) after adjustment for age and sex. A doubling of adiponectin was inversely associated with changes in 2 h glucose (β =−0.063 per year, 95% CI −0.111, −0.014), HOMA-IR (β =−0.038 per year, 95% CI −0.060, −0.015) and HOMA-β (β =−1.028 per year, 95% CI −1.635, −0.421) after adjustment for age and sex. The associations were robust to adjustment for baseline waist circumference and smoking. Adjustment for CRP did not change the associations for sCD163 or adiponectin.

Conclusions/interpretation

Our findings indicate that mechanisms related to inflammation, including macrophage activation and adipocyte metabolism, may play a role in changes in glucose homeostasis in individuals at high risk of type 2 diabetes mellitus.

Nur mit Berechtigung zugänglich

Pickup JC, Crook MA (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241–1248CrossRefPubMed

Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N (2014) Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 105:141–150CrossRefPubMed

McNelis JC, Olefsky JM (2014) Macrophages, immunity, and metabolic disease. Immunity 41:36–48CrossRefPubMed

Moller HJ, Peterslund NA, Graversen JH, Moestrup SK (2002) Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 99:378–380CrossRefPubMed

Weaver LK, Hintz-Goldstein KA, Pioli PA et al (2006) Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol 80:26–35CrossRefPubMed

Moller HJ (2012) Soluble CD163. Scand J Clin Lab Invest 72:1–13CrossRefPubMed

Parkner T, Sorensen LP, Nielsen AR et al (2012) Soluble CD163: a biomarker linking macrophages and insulin resistance. Diabetologia 55:1856–1862CrossRefPubMed

Rojo-Martinez G, Maymo-Masip E, Rodriguez MM et al (2014) Serum sCD163 levels are associated with type 2 diabetes mellitus and are influenced by coffee and wine consumption: results of the Di@bet.es study. PLoS One 9:e101250CrossRefPubMedCentralPubMed

Zanni MV, Burdo TH, Makimura H, Williams KC, Grinspoon SK (2011) Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. Clin Endocrinol (Oxf) 77:385–390CrossRef

10.

Moller HJ, Frikke-Schmidt R, Moestrup SK, Nordestgaard BG, Tybjaerg-Hansen A (2011) Serum soluble CD163 predicts risk of type 2 diabetes in the general population. Clin Chem 57:291–297CrossRefPubMed

11.

Wang ZV, Scherer PE (2016) Adiponectin, the past two decades. J Mol Cell Biol 8:93–100CrossRefPubMedCentralPubMed

12.

Ruan H, Dong LQ (2016) Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol 8:101–109CrossRefPubMedCentralPubMed

13.

Ghoshal K, Bhattacharyya M (2015) Adiponectin: probe of the molecular paradigm associating diabetes and obesity. World J Diabetes 6:151–166CrossRefPubMedCentralPubMed

14.

Sandbaek A, Griffin SJ, Rutten G et al (2008) Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia 51:1127–1134CrossRefPubMedCentralPubMed

15.

Johansen NB, Hansen AL, Jensen TM et al (2012) Protocol for ADDITION-PRO: a longitudinal cohort study of the cardiovascular experience of individuals at high risk for diabetes recruited from Danish primary care. BMC Public Health 12:1078CrossRefPubMedCentralPubMed

16.

D’Orazio P, Burnett RW, Fogh-Andersen N et al (2005) Approved IFCC recommendation on reporting results for blood glucose (abbreviated). Clin Chem 51:1573–1576CrossRefPubMed

17.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed

18.

Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487–1495CrossRefPubMed

19.

Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR (2009) Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373:2215–2221CrossRefPubMedCentralPubMed

20.

Fjeldborg K, Christiansen T, Bennetzen M, J Moller H, Pedersen SB, Richelsen B (2013) The macrophage-specific serum marker, soluble CD163, is increased in obesity and reduced after dietary-induced weight loss. Obesity (Silver Spring) 21:2437–2443CrossRef

21.

Thamer C, Haap M, Heller E et al (2006) Beta cell function, insulin resistance and plasma adiponectin concentrations are predictors for the change of postprandial glucose in non-diabetic subjects at risk for type 2 diabetes. Horm Metab Res 38:178–182CrossRefPubMed

22.

Bennett NR, Boyne MS, Cooper RS et al (2009) Impact of adiponectin and ghrelin on incident glucose intolerance and on weight change. Clin Endocrinol (Oxf) 70:408–414CrossRef

23.

Yamamoto Y, Hirose H, Saito I, Nishikai K, Saruta T (2004) Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab 89:87–90CrossRefPubMed

24.

Kluppelholz B, Thorand B, Koenig W et al (2015) Association of subclinical inflammation with deterioration of glycaemia before the diagnosis of type 2 diabetes: the KORA S4/F4 study. Diabetologia 58:2269–2277CrossRefPubMed

25.

Tabak AG, Brunner EJ, Miller MA et al (2009) Low serum adiponectin predicts 10-year risk of type 2 diabetes and HbA_1c independently of obesity, lipids, and inflammation: Whitehall II study. Horm Metab Res 41:626–629CrossRefPubMedCentralPubMed

26.

Park K, Steffes M, Lee DH, Himes JH, Jacobs DR Jr (2009) Association of inflammation with worsening HOMA-insulin resistance. Diabetologia 52:2337–2344CrossRefPubMedCentralPubMed

27.

Tabak AG, Kivimaki M, Brunner EJ et al (2010) Changes in C-reactive protein levels before type 2 diabetes and cardiovascular death: the Whitehall II study. Eur J Endocrinol 163:89–95CrossRefPubMed

28.

Carstensen B, Lindstrom J, Sundvall J, Borch-Johnsen K, Tuomilehto J, DPS Study Group (2008) Measurement of blood glucose: comparison between different types of specimens. Ann Clin Biochem 45:140–148CrossRefPubMed

29.

Kuwa K, Nakayama T, Hoshino T, Tominaga M (2001) Relationships of glucose concentrations in capillary whole blood, venous whole blood and venous plasma. Clin Chim Acta 307:187–192CrossRefPubMed

30.

Kruijshoop M, Feskens EJ, Blaak EE, de Bruin TW (2004) Validation of capillary glucose measurements to detect glucose intolerance or type 2 diabetes mellitus in the general population. Clin Chim Acta 341:33–40CrossRefPubMed

31.

Manley SE, Stratton IM, Clark PM, Luzio SD (2007) Comparison of 11 human insulin assays: implications for clinical investigation and research. Clin Chem 53:922–932CrossRefPubMed

32.

Gao H, Fall T, van Dam RM et al (2013) Evidence of a causal relationship between adiponectin levels and insulin sensitivity: a Mendelian randomization study. Diabetes 62:1338–1344CrossRefPubMedCentralPubMed

33.

Yaghootkar H, Lamina C, Scott RA et al (2013) Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes 62:3589–3598CrossRefPubMedCentralPubMed

34.

Brunner EJ, Kivimaki M, Witte DR et al (2008) Inflammation, insulin resistance, and diabetes—Mendelian randomization using CRP haplotypes points upstream. PLoS Med 5, e155CrossRefPubMedCentralPubMed

Titel: Soluble CD163, adiponectin, C-reactive protein and progression of dysglycaemia in individuals at high risk of type 2 diabetes mellitus: the ADDITION-PRO cohort
verfasst von: Pia Deichgræber
Daniel R. Witte
Holger J. Møller
Mette V. Skriver
Bjørn Richelsen
Marit E. Jørgensen
Nanna B. Johansen
Annelli Sandbæk
Publikationsdatum: 19.08.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 11/2016
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-016-4075-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Soluble CD163, adiponectin, C-reactive protein and progression of dysglycaemia in individuals at high risk of type 2 diabetes mellitus: the ADDITION-PRO cohort